5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.

[1]  D. Theodorescu,et al.  Y chromosome loss in cancer drives growth by evasion of adaptive immunity , 2023, Nature.

[2]  A. Shokeir,et al.  Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study , 2022, Journal of the Egyptian National Cancer Institute.

[3]  E. McArthur,et al.  5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. , 2022, Urologic oncology.

[4]  Dong Wang,et al.  Re: Vicenç Ruiz de Porras, Xieng C. Wang, Luis Palomero, et al. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol 2021;79:722-33. , 2021, European urology.

[5]  B. Laird,et al.  RELATIONSHIP BETWEEN CYTOKINES AND SYMPTOMS IN PEOPLE WITH INCURABLE CANCER: A SYSTEMATIC REVIEW. , 2021, Critical reviews in oncology/hematology.

[6]  M. Eisenberg,et al.  Increased mortality among men diagnosed with impaired fertility: analysis of US claims data. , 2020, Urology.

[7]  S. Paick,et al.  Clinical significance of 5-α reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review , 2019, The aging male : the official journal of the International Society for the Study of the Aging Male.

[8]  N. Lawrentschuk,et al.  Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study. , 2018, Urologic oncology.

[9]  C. Shyr,et al.  The Genomic Alterations of 5α-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer. , 2017, Anticancer research.

[10]  S. Inoue,et al.  Role of the androgen receptor in urothelial cancer , 2017, Molecular and Cellular Endocrinology.

[11]  K. Bensalah,et al.  Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract , 2017, World Journal of Urology.

[12]  I. Thompson,et al.  Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. , 2016, European urology.

[13]  Steven L. Chang,et al.  Racial Disparities in Postoperative Complications After Radical Nephrectomy: A Population-based Analysis. , 2015, Urology.

[14]  O. Cussenot,et al.  Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old , 2015, Virchows Archiv.

[15]  D. Silverman,et al.  A case-control study of occupational exposure to metalworking fluids and bladder cancer risk among men , 2014, Occupational and Environmental Medicine.

[16]  D. Silverman,et al.  Association between smoking and risk of bladder cancer among men and women. , 2011, JAMA.

[17]  E. Sarchielli,et al.  Sex steroid receptors in male human bladder: expression and biological function. , 2010, The journal of sexual medicine.

[18]  Jie Zhang,et al.  Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.

[19]  M. Carini,et al.  Characterization and functional role of androgen-dependent PDE5 activity in the bladder. , 2007, Endocrinology.

[20]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[21]  Steven L. Chang,et al.  Adoption of Robot-Assisted Partial Nephrectomies: A Population-Based Analysis of U.S. Surgeons from 2004 to 2013. , 2017, Journal of endourology.

[22]  Y. Lotan,et al.  Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines , 2013, International Archives of Occupational and Environmental Health.

[23]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.